A randomized, double-blind, placebo-controlled, single-center human trial to evaluate the efficacy and safety of HK L-137(Heat-Killed L.plantarum L-137) promotion of immunity function

Chong Kun Dang Bio0 个研究点目标入组 100 人开始时间: 待定最近更新: 2023年11月13日

试验速览

暂无简介。

•1) Those who voluntarily decide to participate in this clinical study and signs the informed consent
•2) Men and women aged 19 to 75 years inclusive at the time of signing the informed consent
•3) Those who have at least respiratory infection symptoms twice for more than 12 months prior to screening

•1) Those who are pregnant or lactating women
•2) Those who have a history of alcohol abuse or are chronically consuming alcohol
•3) Those who have a serious accompanying disease inappropriate for participation in the study
•4) Those who have a history of psychiatric diseases or have a disease that interferes with participation in the study
•5) Those who have a disease that can affect the immune response, such as asthma
•6) Those who have a clinically significant liver disorder or kidney disorder
•7) Those who regularly ingested probiotics (lactic acid bacteria, etc.) and prebiotics (e.g., dietary fiber, fructo oligosaccharide, etc.) for one month before screening
•8) Those who continuously takes medicines, etc. that may affect the immune response within one month prior to screening
•9) Those who have a significant infection that is active within three months prior to screening
•10) Those who are required to take drugs continuously that are deemed to affect the results of the study

发起方

Chong Kun Dang Bio